Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Nirogacestat for Desmoid Tumours

Evidence for efficacy is based on the results from the DeFi study
07 Dec 2023
Soft Tissue Sarcomas

On 27 November 2023, the US Food and Drug Administration (FDA) approved nirogacestat (OGSIVEO, SpringWorks Therapeutics, Inc.) for adult patients with progressing desmoid tumours who require systemic treatment. This is the first approved treatment for desmoid tumours.

Full prescribing information for OGSIVEO is available here.

Efficacy was evaluated in DeFi (NCT03785964), an international, multicentre, randomised (1:1), double-blind, placebo-controlled study in 142 patients with progressing desmoid tumours not amenable to surgery. Patients were eligible if the desmoid tumour had progressed within 12 months of screening. Patients were randomised to receive 150 mg nirogacestat or placebo orally twice daily until disease progression or unacceptable toxicity.

The major efficacy outcome measure was progression-free survival (PFS) based on RECIST v1.1 as assessed by blinded independent central review or on clinical progression by the investigator (and adjudicated by independent review). Median PFS was not reached (NR) in the nirogacestat arm (95% confidence interval [CI] NR, NR) and 15.1 months (95% CI 8.4, NR) in the placebo arm (hazard ratio [HR] 0.29; 95% CI 0.15, 0.55; p-value < 0.001). An exploratory analysis of PFS based on only radiographic progression demonstrated a hazard ratio of 0.31 (95% CI 0.16, 0.62).

Objective response rate (ORR) was an additional efficacy outcome measure. ORR was 41% (95% CI 29.8, 53.8) in the nirogacestat arm and 8% (95% CI 3.1, 17.3) for those receiving placebo (p-value < 0.001). Additionally, efficacy results were supported by change from baseline in patient-reported worst pain favouring the nirogacestat arm.

The most common adverse reactions were diarrhoea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, and dyspnoea.

The recommended nirogacestat dose is 150 mg administered orally twice daily with or without food until disease progression or unacceptable toxicity. Each 150 mg dose consists of three 50 mg tablets.

This review used the Real-Time Oncology Review pilot programme, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, breakthrough designation, fast track designation, and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.